Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862371 | 0.83 | DPP4 (0.39) | DPP4DPP7DPP8DPP9KCNH2 | |
| SCHEMBL4868355 | 0.83 | DPP4 (0.46) | DPP4DPP7DPP8DPP9KCNH2 | |
| SCHEMBL3122924 | 0.82 | CCR1 (0.38) | DPP4DPP7KCNH2 | |
| SCHEMBL14003263 | 0.81 | DPP4 (0.39) | DPP4DPP7DPP8DPP9KCNH2 | |
| SCHEMBL14027242 | 0.81 | DPP4 (0.39) | DPP4DPP7DPP8DPP9KCNH2 | |
| SCHEMBL14003264 | 0.79 | DPP4 (0.60) | DPP4DPP7KCNH2 | |
| SCHEMBL8296942 | 0.79 | DPP4 (0.60) | DPP4DPP7KCNH2 | |
| SCHEMBL4867798 | 0.74 | DPP4 (0.61) | DPP4DPP7 | |
| SCHEMBL8276056 | 0.70 | DPP4 (0.40) | DPP4DPP7DPP8DPP9KCNH2 | |
| SCHEMBL5515107 | 0.70 | DPP4 (0.43) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456204-B2 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070021477-A1 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021477-A1 | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.